金河生物
(002688)
| 流通市值：36.92亿 | | | 总市值：41.28亿 |
| 流通股本：7.49亿 | | | 总股本：8.37亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,447,664,288.35 | 741,878,953.16 | 2,878,096,341.01 | 2,036,199,952.22 |
| 营业收入 | 1,447,664,288.35 | 741,878,953.16 | 2,878,096,341.01 | 2,036,199,952.22 |
| 二、营业总成本 | 1,271,446,475.34 | 664,708,394.86 | 2,663,177,540.53 | 1,893,954,187.39 |
| 营业成本 | 900,723,962.75 | 477,565,415.13 | 1,903,598,572.71 | 1,347,392,183.51 |
| 税金及附加 | 11,857,812.62 | 5,038,899.98 | 22,876,984.26 | 17,687,990.61 |
| 销售费用 | 82,750,342.46 | 44,956,626.69 | 166,771,357.38 | 126,845,344.57 |
| 管理费用 | 183,728,870.38 | 91,788,381.87 | 360,974,538.02 | 248,944,376.1 |
| 研发费用 | 42,089,197.42 | 19,443,527.19 | 116,545,317.2 | 85,608,715.73 |
| 财务费用 | 50,296,289.71 | 25,915,544 | 92,410,770.96 | 67,475,576.87 |
| 其中:利息费用 | 41,443,088.63 | 20,288,103.52 | 89,941,609.46 | 65,945,620.8 |
| 其中:利息收入 | 6,499,051.83 | 1,052,239.2 | 8,161,547.5 | 2,966,701.07 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -404,065.76 | -161,581.18 | 229,444.57 | 211,953.9 |
| 加:投资收益 | 11,370.72 | 11,370.72 | -2,627,928.13 | -1,139,097.3 |
| 资产处置收益 | -87,176.3 | -13,047.34 | -2,655,275.01 | 77,451.57 |
| 资产减值损失(新) | -5,145,982.78 | -1,119,995.63 | -192,735,370.65 | -1,102,182.02 |
| 信用减值损失(新) | -3,342,502.31 | -1,884,679.84 | -5,280,050.2 | -1,485,729.62 |
| 其他收益 | 9,983,633.03 | 2,873,656.48 | 30,625,584.13 | 23,000,357.14 |
| 四、营业利润 | 177,233,089.61 | 76,876,281.51 | 42,475,205.19 | 161,808,518.5 |
| 加:营业外收入 | 107,284.81 | 120,705.06 | 486,769.9 | 180,850.31 |
| 减:营业外支出 | 836,820.85 | 24,309.67 | 3,815,316.07 | 1,238,857.46 |
| 五、利润总额 | 176,503,553.57 | 76,972,676.9 | 39,146,659.02 | 160,750,511.35 |
| 减:所得税费用 | 41,326,657.69 | 13,631,804.59 | 50,131,626.99 | 25,970,316.69 |
| 六、净利润 | 135,176,895.88 | 63,340,872.31 | -10,984,967.97 | 134,780,194.66 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 135,176,895.88 | 63,340,872.31 | -10,984,967.97 | 134,780,194.66 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 130,894,115.07 | 62,297,096.94 | 27,556,698.77 | 139,068,189.51 |
| 少数股东损益 | 4,282,780.81 | 1,043,775.37 | -38,541,666.74 | -4,287,994.85 |
| 扣除非经常损益后的净利润 | 125,791,219.35 | 60,001,459.36 | 15,648,322.04 | 124,921,731.12 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.17 | 0.08 | 0.04 | 0.18 |
| (二)稀释每股收益 | 0.17 | 0.08 | 0.04 | 0.18 |
| 八、其他综合收益 | -23,020,964.45 | -10,987,690.87 | -14,129,234.68 | -7,213,099.45 |
| 归属于母公司股东的其他综合收益 | -19,567,819.78 | -9,339,537.24 | -12,009,849.48 | -6,131,134.53 |
| 九、综合收益总额 | 112,155,931.43 | 52,353,181.44 | -25,114,202.65 | 127,567,095.21 |
| 归属于母公司股东的综合收益总额 | 111,326,295.29 | 52,957,559.7 | 15,546,849.29 | 132,937,054.98 |
| 归属于少数股东的综合收益总额 | 829,636.14 | -604,378.26 | -40,661,051.94 | -5,369,959.77 |
| 公告日期 | 2026-08-28 | 2026-04-29 | 2026-04-29 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |